| Name | Title | Contact Details |
|---|
Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.
At Strive Compounding Pharmacy, were pioneering a movement in personalized medicine. Ditching the one-size-fits-all approach, we specialize in customizing medications to fit the unique health conditions and wellness goals of each individual. Our commitment to whole-person health is evident in our comprehensive services ranging from hormone replacement and weight management to dermatology and veterinary care. As a rapidly growing company, we pride ourselves on our robust company culture, strong partnerships with healthcare providers, and the effectiveness, safety, and benefits of our compounded drugs. Our pursuit of uncompromised excellence in compounding, coupled with a proactive approach to healthcare, sets us apart in creating healthier and happier lives, while also educating the world on the crucial role that compound pharmacies play within a healthy society.
Waste Reduction is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Advanced Enzyme Technologies Limited is engaged in business of manufacturing and sale of enzymes. The Companys geographical segments include Within India and Outside India. It provides solutions to industries, such as human healthcare and nutrition, a...
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years before conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.